-
New senior leadership appointments strengthen sales, service and regulatory compliance
-
Timely appointments - approaching anticipated FDA approval for TechnegasTM sales in US market
-
US Sales for TechnegasTM expected in 2020
Cyclopharm Limited (ASX: CYC) is pleased to announce four management appointments. Commenting on the appointments, Cyclopharm Managing Director and CEO, Mr. James McBrayer, said, “We have added a group of very high-quality individuals to our team which will significantly strengthen our global compliance, sales and service capabilities, supporting the next phase of growth at Cyclopharm.”
For more information, download the attached PDF.
Download this document
